Appendix 3B Issue of Options under EOP
Released
Released
Announcement PDF
22 March 2018
Company Announcements Office
Australian Securities Exchange
Issue of Options
Xref Limited (ASX:XF1) (Xref or the Company) advises that 2,749,782 options have
today been issued under the terms of the Employee Option Plan to 25 of its employees
and to the Company’s Chief Financial Officer (CFO). The 249,782 options issued to
the employees have an exercise price of $0.66, vest on 5 February 2019 and will
expire if not exercised by 5 February 2022. The 2,500,000 options issued to Xref’s
CFO have an exercise price of $0.70, vest in three tranches (with the first tranche of
1,000,000 options vesting on 12 February 2018 and expiring if not exercised by
12 February 2021, the second tranche of 750,000 options vesting on 12 February 2019
and expiring if not exercised by 12 February 2022, and the third tranche of 750,000
options vesting on the later of 12 February 2020 or when the Company achieves cash
flow breakeven and expiring if not exercised by 12 February 2023).
An Appendix 3B for the issue of these options is attached.
Xref Limited
Robert J Waring
Company Secretary
Cleansing Statement – Notice under Section 708A(5)(e)
As at 22 March 2018, Xref Limited gives notice under section 708A(5)(e) of the
Corporations Act 2001 (Cth) (Corporations Act) that:
1.
2.
3.
the Company issued the abovementioned securities without disclosure to
investors under Part 6D.2 of the Corporations Act.
the Company has complied with the provisions, as they apply to the Company, of
Chapter 2M of the Corporations Act and with Section 674 of the Corporations Act; and
there is no information:
a.
that has been excluded from a continuous disclosure notice in accordance
with the ASX Listing Rules; or
b.
that investors and their professional advisors would reasonably require for
the purpose of making an informed assessment of the assets and liabilities,
financial performance, profits and losses and prospects of Xref Limited, or
the rights and liabilities attaching to Xref Limited ordinary shares.
Xref Limited (ASX:XF1)
ABN 34 122 404 666
Suite 14, Level 3, 13 Hickson Road, Dawes Point, Sydney NSW 2000 Australia
Website: xref.com
Appendix 3B
New issue announcement
Appendix 3B
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
04/03/13
Name of entity
Xref Limited (ASX:XF1)
ABN
34 122 404 666
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to
2
Number of +securities issued or to
be issued (if known) or maximum
number which may be issued
3
Principal terms of the +securities
(e.g. if options, exercise price and
expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
+convertible
payment;
if
securities, the conversion price
and dates for conversion)
be issued
Options
2,749,782
All 2,749,782 options were issued under the
terms of the Employee Option Plan (EOP).
There were 249,782 options issued to
employees with an exercise price of $0.66,
which vest on 5 February 2019 and will
expire if not exercised by 5 February 2022.
There were 2,500,000 options issued to Xref’s
CFO with an exercise price of $0.70, which vest
in three tranches (with the first tranche of
1,000,000 options vesting on 12 February
2018 and expiring if not exercised by 12 February
2021, the second tranche of 750,000 options
vesting on 12 February 2019 and expiring if not
exercised by 12 February 2022, and the third
tranche of 750,000 options vesting on the later
of 12 February 2020 or when the Company
achieves cash flow breakeven and expiring if not
exercised by 12 February 2023).
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 1
Appendix 3B
New issue announcement
4
Do the +securities rank equally in
all respects from the +issue date
with an existing +class of quoted
+securities?
If the additional +securities do
not rank equally, please state:
the date from which they do
the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment
5
Issue price or consideration
Any fully paid ordinary shares issued, if and
when the options are exercised, will rank
equally with the Company’s existing fully
paid ordinary shares.
The 249,782 options issued to the employees
have an exercise price of $0.66.
The 2,500,000 options issued to the CFO have
an exercise price of $0.70.
All options were issued for no consideration
under the terms of the EOP.
6
Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)
6a
Is the entity an +eligible entity
that has obtained security holder
approval under rule 7.1A?
2,749,782 options issued under the terms of
the EOP to 25 of Xref’s employees and its CFO.
Yes
If Yes, complete sections 6b – 6h
in relation to the +securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder resolution
under rule 7.1A was passed
6c
Number of +securities issued
without security holder approval
under rule 7.1
Not applicable
6d
Number of +securities issued
with security holder approval
under rule 7.1A
Not applicable
The Company received shareholder approval
at its Annual General Meeting held on
20 November 2017 under ASX Listing Rule 7.1A.
+ See chapter 19 for defined terms.
Appendix 3B Page 2
04/03/2013
Appendix 3B
New issue announcement
Number of +securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
Not applicable
6f
Number of +securities issued
under an exception in rule 7.2
2,749,782
6g
If +securities issued under rule 7.1A,
was the issue price at least 75% of
15 day VWAP as calculated under
rule 7.1A.3? Include the +issue date
and both values. Include the source
of the VWAP calculation.
Not applicable
If +securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which valuation of consideration
was released to ASX Market
Announcements
Not applicable
Calculate the entity’s remaining issue
capacity under rule 7.1 and rule 7.1A –
complete Annexure 1 and release to
ASX Market Announcements
36,683,589
6e
6h
6i
7
+Issue dates
Note: The issue date may be prescribed by ASX
(refer to the definition of issue date in rule
19.12). For example, the issue date for a pro
rata entitlement issue must comply with the
applicable timetable in Appendix 7A.
22 March 2018
Cross reference: item 33 of Appendix 3B.
8
Number and +class of all
+securities
quoted on ASX
(including the +securities in
section 2 if applicable)
Number
+Class
147,736,127
Fully paid ordinary shares
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 3
Appendix 3B
New issue announcement
9
+class
Number and
of all
+securities not quoted on ASX
(including the +securities in
section 2 if applicable)
Number
+Class
16,666,666
C Class Performance Rights *
4,508,909
Options – will expire, if not
exercised, by 1 February 2019 –
exercise price $0.23 (all of which
have vested).
7,000,000
Options – 4,500,000 of the Options
will expire, if not exercised, by
25 November 2021 and 2,500,000
of the Options will expire, if not
exercised, by 25 November 2022.
All have an exercise price of $0.70
(2,000,000 of which have vested,
2,500,000 will vest on
25 November 2018 and 2,500,000
will vest on 25 November 2019).
900,000
Options – will expire, if not
exercised, by 25 November 2021.
All have an exercise price of $0.70
(all of which have vested, except
for 300,000, which vest on
18 August 2018).
1,055,499
Options – issued under the EOP,
with an exercise price of $0.585
(which vest on 3 July 2018) and
will expire if not exercised by
3 July 2021.
249,782
Options – issued under the EOP,
with an exercise price of $0.66
(which vest on 5 February 2019)
and will expire if not exercised by
5 February 2022.
2,500,000
Options – issued under the EOP,
with an exercise price of $0.70, (with
1,000,000 options vesting on 12
February 2018 and expiring if not
exercised by 12 February 2021, with
750,000 options vesting on
12 February 2019 and expiring if not
exercised by 12 February 2022, and
with 750,000 options vesting on the
later of 12 February 2020 or when
the Company achieves cash flow
breakeven and expiring if not
exercised by 12 February 2023).
* The conversion ratio of the
Performance Rights into
ordinary shares upon
achievement of the relevant
Performance Milestone is one
ordinary share for each
Performance Right.
+ See chapter 19 for defined terms.
Appendix 3B Page 4
04/03/2013
Appendix 3B
New issue announcement
10
Dividend policy (in the case of a
trust, distribution policy) on the Any fully paid ordinary shares issued on the
exercise of options will have full
increased capital (interests)
participation in any future dividends.
Part 2 - Pro rata issue
Questions 11 to 33 are not applicable
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of +securities
(tick one)
(a)
+Securities described in Part 1
(b)
All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee
incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or documents
35
+
+
If the securities are equity securities, the names of the 20 largest holders of the
additional securities, and the number and percentage of additional securities
+
+
held by those holders
36
+
+
If the securities are equity securities, a distribution schedule of the additional
securities setting out the number of holders in the categories
+
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
+
A copy of any trust deed for the additional securities
Entities that have ticked box 34(b)
Questions 38 to 42 are not applicable
Quotation agreement
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 5
Appendix 3B
New issue announcement
1
+Quotation of our additional +securities is in ASX’s absolute discretion.
2
We warrant the following to ASX.
may quote the +securities on any conditions it decides.
ASX
The issue of the +securities to be quoted complies with the law and is
not for an illegal purpose.
There is no reason why those +securities should not be granted +quotation.
An offer of the +securities for sale within 12 months after their issue
will not require disclosure under section 707(3) or section 1012C(6) of
the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able
to give this warranty
Section 724 or section 1016E of the Corporations Act does not apply to
any applications received by us in relation to any +securities to be
quoted and that no-one has any right to return any +securities to be
quoted under sections 737, 738 or 1016F of the Corporations Act at the
time that we request that the +securities be quoted.
If we are a trust, we warrant that no person has the right to return the
+securities to be quoted under section 1019B of the Corporations Act at
the time that we request that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any
claim, action or expense arising from or connected with any breach of the
warranties in this agreement.
4
We give ASX the information and documents required by this form. If any
information or document is not available now, we will give it to ASX before +quotation
of the +securities begins. We acknowledge that ASX is relying on the information and
documents. We warrant that they are (will be) true and complete.
Sign here:
Print name:
(Director/Company Secretary)
Date: 22 March 2018
Robert J Waring
== == == == ==
+ See chapter 19 for defined terms.
Appendix 3B Page 6
04/03/2013
Appendix 3B
New issue announcement
Appendix 3B – Annexure 1
Calculation of placement capacity under rule 7.1 and rule 7.1A for
eligible entities
Introduced 01/08/12 Amended 04/03/13
Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insert number of fully paid +ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
118,368,906
Add the following:
•
Number of fully paid +ordinary securities
issued in that 12-month period under an
exception in rule 7.2
16,667,667
•
Number of fully paid +ordinary securities
issued in that 12-month period with
shareholder approval
12,500,000
Number of partly paid +ordinary
securities that became fully paid in that
12-month period
Nil
•
Note:
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid
+ordinary securities cancelled during that
12-month period
Nil
“A”
147,536,573
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 7
Appendix 3B
New issue announcement
Step 2: Calculate 15% of “A”
“B”
0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15
22,130,486
Step 3: Calculate “C”, the amount of placement capacity under rule
7.1 that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12-month
period not counting those issued:
•
Under an exception in rule 7.2
•
Under rule 7.1A
•
With security holder approval under rule
7.1 or rule 7.4
Note:
• This applies to equity securities,
unless specifically excluded – not just
ordinary securities
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
“C”
200,554
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
22,130,486
Note: number must be same as shown in
Step 2
Subtract “C”
200,554
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C”
21,929,932
[Note: this is the remaining placement
capacity under rule 7.1]
Part 2
+ See chapter 19 for defined terms.
Appendix 3B Page 8
04/03/2013
Appendix 3B
New issue announcement
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
147,536,573
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D”
0.10
Note: this value cannot be changed
Multiply “A” by 0.10
14,753,657
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12-month
period under rule 7.1A
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix 3B
to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
“E”
Nil
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 9
Appendix 3B
New issue announcement
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
14,753,657
Note: number must be same as shown in
Step 2
Subtract “E”
Nil
Note: number must be same as shown in
Step 3
Total [“A” x 0.10] – “E”
14,753,657
Note: this is the remaining placement
capacity under rule 7.1A
+ See chapter 19 for defined terms.
Appendix 3B Page 10
04/03/2013
Share your feedback
Discover